Michael Barbella, Managing Editor03.25.21
OrthoPediatrics Corp. is marking two milestones for its ApiFix technology: More than 500 procedures performed on young adolescent idiopathic scoliosis (AIS) patients on three continents, and long-term clinical follow-up exceeding nine years.
“These are significant milestones for this revolutionary technology and the patients it has benefited all over the world,” said David Bailey, president of OrthoPediatrics. “OrthoPediatrics remains committed to providing innovative and game-changing solutions to pediatric caregivers, therapists and surgeons that better enable them to treat their patients.”
The ApiFix procedure offers select AIS patients a less invasive, motion-preserving option for achieving curve correction – without the permanence of fusion. The ApiFix system’s novel approach to correcting spinal deformity is a medical advancement that has the ability to disrupt the continuum of care for scoliosis treatment in certain pediatric patients. Its elegant design and biomechanical considerations combined with the simplistic posterior approach is unmatched, according to the company.
“Our continued review of the extensive clinical experience with the ApiFix system and our ongoing collection of new data continue to underscore ApiFix’s positive and encouraging results realized in patients with progressive spinal deformity,” commented Daphna Zaroor Regev, Ph.D., director of Clinical Affairs at ApiFix Ltd. “We are committed to establishing a new standard of care for spinal deformity treatment and generating peer-reviewed clinical evidence to support its use.”
The company has recruited 20 leading clinical centers in the United States to enter data related to the use of the ApiFix system into a post-approval study registry hosted by the Pediatric Spine Study Group. The registry will continue to monitor the safety and probable benefit of the procedure for the treatment of progressive AIS. A typical ApiFix surgical procedure is completed in less than two hours with minimal blood loss (<50cc) and requires a hospital stay of only one or two days. Patient recovery is relatively pain-free and is measured in days, not months, with children able to return to school in just several weeks. The ApiFix MID-C System has U.S. Food and Drug Administration and CE Mark approvals.
ApiFix‘s unique technology is supported by strong intellectual property protection, including 46 issued patents and 30 additional patent applications worldwide. ApiFix, a leader in motion-preserving scoliosis correction, was acquired by OrthoPediatrics in April 2020 and operates as a wholly-owned subsidiary based in Israel.
“These are significant milestones for this revolutionary technology and the patients it has benefited all over the world,” said David Bailey, president of OrthoPediatrics. “OrthoPediatrics remains committed to providing innovative and game-changing solutions to pediatric caregivers, therapists and surgeons that better enable them to treat their patients.”
The ApiFix procedure offers select AIS patients a less invasive, motion-preserving option for achieving curve correction – without the permanence of fusion. The ApiFix system’s novel approach to correcting spinal deformity is a medical advancement that has the ability to disrupt the continuum of care for scoliosis treatment in certain pediatric patients. Its elegant design and biomechanical considerations combined with the simplistic posterior approach is unmatched, according to the company.
“Our continued review of the extensive clinical experience with the ApiFix system and our ongoing collection of new data continue to underscore ApiFix’s positive and encouraging results realized in patients with progressive spinal deformity,” commented Daphna Zaroor Regev, Ph.D., director of Clinical Affairs at ApiFix Ltd. “We are committed to establishing a new standard of care for spinal deformity treatment and generating peer-reviewed clinical evidence to support its use.”
The company has recruited 20 leading clinical centers in the United States to enter data related to the use of the ApiFix system into a post-approval study registry hosted by the Pediatric Spine Study Group. The registry will continue to monitor the safety and probable benefit of the procedure for the treatment of progressive AIS. A typical ApiFix surgical procedure is completed in less than two hours with minimal blood loss (<50cc) and requires a hospital stay of only one or two days. Patient recovery is relatively pain-free and is measured in days, not months, with children able to return to school in just several weeks. The ApiFix MID-C System has U.S. Food and Drug Administration and CE Mark approvals.
ApiFix‘s unique technology is supported by strong intellectual property protection, including 46 issued patents and 30 additional patent applications worldwide. ApiFix, a leader in motion-preserving scoliosis correction, was acquired by OrthoPediatrics in April 2020 and operates as a wholly-owned subsidiary based in Israel.
